

IN THE CLAIMS

Amend claims 15, 16, and 19 to read:

15. (once amended) A compound according to claim 1 of formula I, wherein  $R_1$  is 4-pyridyl, N-oxido-4-pyridyl, or 3-indolyl, and  $R_7$  is fluoro-substituted alkoxy containing up to 2 carbon atoms, or a salt of such a compound containing at least one salt-forming group.

16. (once amended) A compound of formula I according to claim 1, wherein  $R_1$  is 4-pyridyl, N-oxido-4-pyridyl, or 3-indolyl, and  $R_7$  is trifluoromethoxy or 1,1,2,2-tetrafluoroethoxy, or a salt of such a compound containing at least one salt-forming group.

19. (once amended) A compound according to claim 1 of the formula I or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group selected from N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-Chlorobenzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-(3-Benzoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(2-Pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(3-pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-(3-Pentafluoro-benzoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(2-Carboxy-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-(3-n-Hexanoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine, N-(3-Nitro-phenyl)-4-(2-pyridyl)-2-pyrimidine-amine, N-(3-Nitro-phenyl)-4-(4-pyridyl)-2-pyrimidine-amine, N-[3-(2-Methoxy-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-Fluoro-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-Cyano-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(2-Thienylcarboxamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-(3-Cyclohexycarboxamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-Methyl-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine, N-[3-(4-Chloro-benzoylamido)-phenyl]-4-(4-pyridyl)-2-pyrimidine-amine, N-[3-(4-Methyl-piperazinomethyl)-benzoylamido]-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

*OR*  
*contd*

[N-{5-[4-(4-Methyl-piperazino-methyl)-benzoylamido]-2-methyl-phenyl}-4-(3-pyridyl)-2-pyrimidine-amine, ]  
N-[5-(4-Methyl-benzoylamido)-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,  
N-[5-(2-Naphthoylamido)-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,  
N-[5-(4-Chloro-benzoylamido)-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,  
N-[5-(2-Methoxy-benzoylamido)-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,  
N-(3-Trifluoromethoxy-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,  
N-(3-[1,1,2,2-tetrafluoro-ethoxy]-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,  
N-(3-Nitro-5-methyl-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,  
N-(3-Nitro-5-trifluoromethyl-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,  
N-(3-Nitro-phenyl)-4-(N-oxido-3-pyridyl)-2-pyrimidine-amine,  
N-(3-Benzoylamido-5-methyl-phenyl)-4-(N-oxido-3-pyridyl)-2-pyrimidine-amine and the pharmaceutically acceptable salts of such a compound having at least one salt-forming group.

Cancel claim 23 subject to Applicants right to refile this non-elected subject matter in a divisional application.

Insert new claim 24 to read:

*23* 24. The compound according to claim 1 of the formula I, said compound being N-{5-[4-(4-Methyl-piperazino-methyl)-benzoylamido]-2-methyl-phenyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt thereof.

#### STATUS OF THE CLAIMS

Claims 1-23 were pending.

Claims 1-23 have been restricted.

Claims 1-3, 6-7, 10, and 21-22 have been rejected under 35 U.S.C. § 112, first paragraph.

Claims 15, 16, and 19 have been rejected under 35 U.S.C. § 112, second paragraph.

Claims 4, 5, 8-9, 12-14, 18, and 20 have been objected to as being dependent upon a rejected base claim.

Claims 15, 16, and 19 have been amended.

Claim 23 has been canceled subject to Applicants' right to refile this non-elected subject matter in a divisional application.

Claim 24 has been added.

Claims 1-24 are presented for reconsideration.

#### REMARKS

Claims 1-23 have been restricted between: claims 1-22 directed to compounds, compositions, and methods of use; and claim 23 directed to a process of making such compounds. Applicants confirm the election of group I, claims 1-22. Claim 23 has been canceled subject to Applicants right to refile the non-elected subject matter in a divisional application.

Claims 1-3, 6-7, 10, and 21-22 have been rejected under 35 U.S.C. § 112 for lack of enablement because the source of the starting materials of formula VII wherein R<sub>1</sub> is a radical bonded through a ring nitrogen is allegedly not disclosed in the specification. 4-Pyrazinyl is the only radical R<sub>1</sub> which is bonded through a ring nitrogen. Benzimidazolyl is not disclosed by the instant specification. Indolyl is explicitly claimed to be bonded only at